Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Breast Cancer With Active Brain Metastasis”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Early research (Phase 1)Study completedNCT01770353
What this trial is testing

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Who this might be right for
Solid TumorsER/PR Positive Breast CancerTriple Negative Breast Cancer+1 more
Ipsen 45
Not applicableNot Yet RecruitingNCT07619534
What this trial is testing

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

Who this might be right for
Breast CancerBreast CarcinomaCancer of the Breast+1 more
National Cancer Institute (NCI) 139
Testing effectiveness (Phase 2)Study completedNCT05865990
What this trial is testing

HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease

Who this might be right for
Metastatic Breast CancerAdvanced Non-Small Cell Squamous Lung CancerSolid Tumor, Adult
MedSIR 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06475443
What this trial is testing

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Who this might be right for
Metastatic Breast Cancer in the Brain
Henan Cancer Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07458113
What this trial is testing

Sac-TMT for Active TNBC Brain Metastases

Who this might be right for
Metastatic Triple Negative Breast Cancers
Yale University 20
Testing effectiveness (Phase 2)Study completedNCT00110045
What this trial is testing

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Who this might be right for
Cancer
European Organisation for Research and Treatment of Cancer - EORTC 171
Testing effectiveness (Phase 2)Looking for participantsNCT06598046
What this trial is testing

A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 48
Testing effectiveness (Phase 2)Looking for participantsNCT04965064
What this trial is testing

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Who this might be right for
Breast Cancer
University of Rochester 22
Early research (Phase 1)Study completedNCT04456140
What this trial is testing

Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study

Who this might be right for
Breast CarcinomaDigestive System NeoplasmMalignant Brain Neoplasm+8 more
Mayo Clinic 230
Testing effectiveness (Phase 2)Looking for participantsNCT06907043
What this trial is testing

PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Who this might be right for
Advanced Solid Tumors
Eikon Therapeutics 130
Testing effectiveness (Phase 2)Active Not RecruitingNCT04538742
What this trial is testing

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 245